CAR-NK exists as a category because of a single biological fact: NK cells carry a markedly lower graft-versus-host risk than T cells, which makes an allogeneic off-the-shelf product plausible without engineering that risk away first. Everything else about the modality, including its difficulties, follows from decisions about where the cells come from.
The result that changed expectations
CD19-directed CAR-NK cells manufactured from cord blood produced responses in relapsed or refractory CD19-positive lymphoid malignancy without the cytokine release syndrome and neurotoxicity that characterize the CAR-T safety profile, and without graft-versus-host disease despite being allogeneic and not HLA-matched (Liu et al., Leukemia 2018; trial NCT03056339).
That combination, activity with a materially different safety profile from an unmatched allogeneic product, is what moved cord blood from an interesting source to a strategic one.
Where CAR-NK cells come from
| Source | Advantage | Constraint |
|---|---|---|
| Cord blood | Naive cells that expand extensively without the usual exhaustion | Fixed single collection, bounded cell number, no donor recall |
| Adult peripheral blood | Mature, immediately cytotoxic, donor can be recalled | Less expansion headroom than cord blood |
| NK-92 and related lines | Uniform and convenient | Not a primary cell; the parent line lacks CD16, so no ADCC |
| iPSC-derived | A renewable, editable starting point | Differentiation adds a substantial process layer |
The choice is not primarily about cost. Each source produces cells with different expansion behavior, different persistence characteristics and different baseline function, and switching later means repeating characterization rather than swapping a reagent.
Related product
Leukopak formats. Single-donor starting material, fresh or cryopreserved, with full donor documentation.
The inhibitory arm keeps working
A chimeric receptor adds an activating signal. It does not remove the inhibitory signalling NK cells already carry, and killer immunoglobulin-like receptors continue reading HLA class I on the target throughout.
Which means a donor whose inhibitory repertoire is strongly engaged against your target antigen’s cellular context makes a poor backbone regardless of construct quality. Selecting donors on KIR genotype is therefore not a refinement, it is part of choosing the platform. The reasoning is set out in KIR genotyping.
Persistence is the open problem
NK cells persist for a shorter period after infusion than CAR-T cells do, which is part of why the safety profile is gentler and also the principal limitation on durability. Approaches to extending persistence, including cytokine support and armouring strategies, are an active area rather than a solved one.
This shapes what a development program should measure. Peak activity is easier to demonstrate than durable activity, and a construct selected purely on early cytotoxicity may not be the one that performs where persistence matters.
Manufacturing from a variable input
Expansion is central to NK manufacturing because starting numbers are usually limiting, and expansion behavior is donor-dependent. A protocol tuned on one donor may perform differently on the next, which makes donor characterization part of process development rather than a procurement concern.
OrganaBio documents CD56+ NK cells from cord blood at 1 or 2.5 million cells per vial with viability and CD56+ purity each listed at 90% or above, and CD56+ NK cells from peripheral blood at 5 or 10 million cells per vial with post-thaw viability listed at 85% or above, in research and cGMP formats. Both sit on a donor program documenting high-resolution NGS HLA typing across six genes and KIR genotyping. Broader biology is in the NK cell guide.
Frequently asked questions
Why are NK cells attractive for allogeneic cell therapy?
Because they carry a markedly lower graft-versus-host disease risk than T cells, which makes an off-the-shelf allogeneic product plausible without first engineering that risk away.
What did the cord blood CAR-NK results demonstrate?
CD19-directed CAR-NK cells from cord blood produced responses in relapsed or refractory CD19-positive lymphoid malignancy without the cytokine release syndrome and neurotoxicity typical of CAR-T, and without graft-versus-host disease despite being allogeneic and unmatched.
Which NK source should a CAR-NK program use?
Cord blood offers naive cells with extensive expansion capacity but a fixed collection with no donor recall. Adult peripheral blood offers mature cells and donor recall with less expansion headroom. Cell lines offer uniformity but are not primary cells, and iPSC-derived cells add a differentiation layer.
Does a chimeric antigen receptor override NK inhibitory signalling?
No. The construct adds an activating signal while killer immunoglobulin-like receptors continue reading HLA class I on the target. A donor whose inhibitory repertoire is strongly engaged makes a poor backbone regardless of construct quality.
Why should CAR-NK donors be selected on KIR genotype?
Because construct performance measured across donors of unknown KIR genotype produces a spread that looks like construct variability and is actually donor biology. Genotype selection is part of choosing the platform rather than a refinement.
What is the main limitation of CAR-NK compared with CAR-T?
Shorter persistence after infusion, which contributes to the gentler safety profile and also limits durability. Extending persistence through cytokine support and armouring strategies is an active research area rather than a solved problem.
Why does donor variability complicate NK manufacturing?
Expansion is central because starting numbers are usually limiting, and expansion behavior is donor-dependent. A protocol tuned on one donor may perform differently on the next, making donor characterization part of process development.
Talk to OrganaBio
Working through this on a live program?
The scientific team works through sourcing and specification questions with cell therapy and research groups directly, including donor characterization, format selection and documentation scope.
